U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07223840) titled 'A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse' on Oct. 31.
Brief Summary: This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit.
Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-week treatment period, 8-week safety follow-up period.
.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Smoking
Intervention:
DRUG: Brenipatide
Administered SC
DRUG: Placebo
Administered SC
Recru...